STOCK TITAN

Quidel Stock Price, News & Analysis

QDEL NASDAQ

Company Description

Overview

QuidelOrtho Corporation (symbol: QDEL) is an American diagnostic healthcare manufacturer that specializes in rapid diagnostic testing solutions. The company is renowned for its innovative approaches in rapid diagnostic testing, immunoassay, and molecular diagnostics, offering products that enable clinicians and laboratories worldwide to quickly and accurately diagnose medical conditions.

Core Business Areas

QuidelOrtho develops, manufactures, and markets a wide range of diagnostic products across several key segments. Its product portfolio includes:

  • Immunoassay Testing: Designed to detect a variety of biological markers, these tests help in early and rapid disease detection.
  • Molecular Diagnostics: Utilizing nucleic acid amplification, these solutions provide high sensitivity and specificity in detecting pathogens and genetic markers.
  • Clinical Chemistry: The company leverages advanced technology to perform biochemical assays that aid clinical decision-making.
  • Transfusion Medicine: This segment supports safe blood management and compatibility testing in healthcare settings.

Global Footprint

Operating on a global scale, QuidelOrtho maintains a significant presence in North America while extending its reach to EMEA, China, and other international markets. This geographic diversity allows the company to adapt its product offerings to various regulatory environments and healthcare needs around the world, reinforcing its commitment to improving patient care globally.

Market Position and Competitive Landscape

In the highly competitive diagnostic healthcare industry, QuidelOrtho distinguishes itself through its focus on rapid, reliable testing solutions that meet the evolving needs of modern clinical practice. The company faces competitive pressures from other diagnostic manufacturers; however, its continued emphasis on research, technological innovation, and quality manufacturing processes has carved out a robust position in the market. Its strategy is built on addressing the challenges of timely diagnosis, which is critical for effective treatment and patient management.

Value Proposition and Business Model

The core value of QuidelOrtho lies in its ability to deliver quick, accurate, and reliable diagnostic results. This capability is essential for the effective treatment of patients, particularly in settings where speed is of the essence. The company generates revenue primarily through the direct sale of its diagnostic products to hospitals, clinics, and laboratories. Its business model is supported by a strong emphasis on technological innovation, quality assurance, and compliance with industry and regulatory standards, ensuring that its products remain at the forefront in the competitive diagnostic landscape.

Expertise and Innovation

QuidelOrtho exemplifies the integration of technology and medicine, offering diagnostic solutions that empower healthcare professionals to make informed decisions swiftly. By continuously investing in research and development, the company not only meets current market demands but also anticipates the needs of the evolving diagnostic market. The emphasis on product quality and technological sophistication underscores the company’s credibility and authority within the diagnostic sector.

Summary

Overall, QuidelOrtho Corporation represents a comprehensive approach to diagnostic healthcare. Its diversified product portfolio, global reach, and commitment to rapid and precise diagnostic testing underscore its significance as a major player in the industry. The company's focus on reinvigorating traditional diagnostic methods with innovative technologies continues to set it apart, establishing a strong foundation built on expertise, quality, and a deep understanding of the diagnostic landscape.

Stock Performance

$29.91
+0.03%
+0.01
Last updated: June 6, 2025 at 11:43
-28.94 %
Performance 1 year
$2.1B
Market Cap
67.6M
Shares outstanding

SEC Filings

No SEC filings available for Quidel.

Financial Highlights

$2,782,900,000
Revenue (TTM)
-$2,052,000,000
Net Income (TTM)
-$30.54
Diluted EPS (TTM)
$83,000,000
Operating Cash Flow
-73.74%
Net Profit Margin
-70.46%
Oper. Profit Margin

Upcoming Events

June 5, 2025
Jefferies fireside chat
Live webcast and replay via QuidelOrtho investor relations website
September 1, 2025 - April 30, 2026
FDA 510(k) clearance
Expected FDA clearance enabling ~$100M LEX Diagnostics acquisition

Frequently Asked Questions

What is the current stock price of Quidel (QDEL)?

The current stock price of Quidel (QDEL) is $29.9 as of June 5, 2025.

What is the market cap of Quidel (QDEL)?

The market cap of Quidel (QDEL) is approximately 2.1B.

What is the revenue (TTM) of Quidel (QDEL) stock?

The trailing twelve months (TTM) revenue of Quidel (QDEL) is $2,782,900,000.

What is the net income of Quidel (QDEL)?

The trailing twelve months (TTM) net income of Quidel (QDEL) is -$2,052,000,000.

What is the earnings per share (EPS) of Quidel (QDEL)?

The diluted earnings per share (EPS) of Quidel (QDEL) is -$30.54 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Quidel (QDEL)?

The operating cash flow of Quidel (QDEL) is $83,000,000.

What is the profit margin of Quidel (QDEL)?

The net profit margin of Quidel (QDEL) is -73.74%.

What is the operating margin of Quidel (QDEL)?

The operating profit margin of Quidel (QDEL) is -70.46%.

What is the current ratio of Quidel (QDEL)?

The current ratio of Quidel (QDEL) is 1.22, indicating the company's ability to pay short-term obligations.

What is the operating income of Quidel (QDEL)?

The operating income of Quidel (QDEL) is -$1,960,900,000.

What is the core business of QuidelOrtho Corporation?

QuidelOrtho Corporation specializes in the development, manufacturing, and marketing of rapid diagnostic testing solutions used in immunoassay, molecular diagnostics, clinical chemistry, and transfusion medicine.

Which healthcare segments does QuidelOrtho serve?

The company serves multiple segments including immunoassay testing, molecular diagnostics, clinical chemistry, and transfusion medicine, all of which are critical for accurate and timely patient diagnosis.

How does QuidelOrtho generate its revenue?

Revenue is generated primarily through the direct sale of diagnostic products to hospitals, clinics, and laboratories across various international markets, with a significant contribution from North America.

What differentiates QuidelOrtho from other diagnostic manufacturers?

The company differentiates itself through a strong focus on rapid and reliable testing solutions, a diversified product portfolio, and continuous investment in technological innovation and research.

Where does QuidelOrtho have a global presence?

QuidelOrtho operates internationally with established markets in North America, EMEA, China, and other regions, allowing it to cater to a diverse set of regulatory and healthcare needs.

What role does innovation play in QuidelOrtho's business model?

Innovation is central to QuidelOrtho’s operations, as the company constantly invests in research and development to improve the speed, accuracy, and reliability of its diagnostic testing solutions.

How does QuidelOrtho contribute to clinical decision-making?

By providing rapidly available and precise diagnostic results, QuidelOrtho’s products assist clinicians in making informed treatment decisions, thereby enhancing patient care and clinical outcomes.

What are some common applications of QuidelOrtho's diagnostic tests?

Their tests are widely used in clinical settings for disease detection, patient monitoring, and ensuring the safety and efficacy of transfusion services, among other applications.